Clinical Trial Detail

NCT ID NCT02652871
Title A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Cytarabine + Idarubicin + LY2510924

Age Groups: adult

No variant requirements are available.